Alliance to Protect Medical Innovation

We are committed to preserving the pipeline of breakthrough medicines that reduce costs and help people live longer, healthier, and more productive lives.

[Alliance to Protect Medical Innovation @ProtectMedicine]

Pharmacy benefit managers (PBMs) increase prescription #drugprices by pocketing portions of negotiated rebates intended for customers. Arkansas is fighting to uphold its law that regulates PBMs to keep drug costs down: https://t.co/0IPgTKICVR

[Alliance to Protect Medical Innovation @ProtectMedicine]

.@AgiosPharma’s drug mitapivat achieved the primary goal of its Phase 3 clinical trials--increasing hemoglobin levels in patients with a rare form of anemia called PK deficiency. https://t.co/EE3oC1waZ2 #innovation @adamfeuerstein

[Alliance to Protect Medical Innovation @ProtectMedicine]

Pharmacy benefit managers (PBMs) are not regulated and their corporate members accept no contractual responsibility to control expenditures. https://t.co/oEWTK4lP9j #drugprices

[Alliance to Protect Medical Innovation @ProtectMedicine]

Brain tumors are some of the most common and deadly cancers in children. Researchers’ breakthrough study of pediatric brain tumors offers new clues to how brain cancer in children may be treated: https://t.co/yMibYonBBV #innovation @megkesh

[Alliance to Protect Medical Innovation @ProtectMedicine]

A new gene-editing treatment has the possibility to cure sickle cell disease. The treatment alters CRISPR DNA in patients’ stem cells to cut out the gene that causes sickle cell disease. https://t.co/8wjX8JQAUF #innovation

[Alliance to Protect Medical Innovation @ProtectMedicine]

.@C2NDiagnostics developed the first blood test to develop #alzheimers disease. The test could make it easier for patients to learn if they have #dementia. https://t.co/bsF1s4qEnj #innovation

[Alliance to Protect Medical Innovation @ProtectMedicine]

Government controls on #drugprices limit #biopharma #innovation. When European countries adopted price controls in the 1980s, they "pushed the locus of R&D investment away from the continent to countries with more pro-innovation policies," like the U.S. https://t.co/eGcSLNVAol

[Alliance to Protect Medical Innovation @ProtectMedicine]

A Florida report found that pharmacy benefit managers (PBMs) pocketed more than $89 million of the rebates they negotiated on behalf of the Florida Medicaid program. Patients paid more for their drugs because PBMs made $8.64 per Medicaid prescription: https://t.co/pCid0ray34

[Alliance to Protect Medical Innovation @ProtectMedicine]

"It makes no sense for the Trump administration to rush a last-minute proposal in its final days that threatens the #innovation we so desperately need." Read our statement on the most-favored nation proposal: https://t.co/tjllIve6D6 #drugprices #pricecontrols

[Alliance to Protect Medical Innovation @ProtectMedicine]

In a new study, researchers from @WUSTL found that the antidepressant fluvoxamine prevented symptoms from worsening in nonhospitalized #COVID19 patients. https://t.co/nlrOARIJl1 #innovation @cooney_liz @matthewherper

[Alliance to Protect Medical Innovation @ProtectMedicine]

.@CureVacRNA's #COVID19 vaccine produced strong immune responses in early clinical trials. CureVac's approach to the vaccine could revolutionize the entire prophylactic vaccine field. https://t.co/WhidgahiXB #innovation

[Alliance to Protect Medical Innovation @ProtectMedicine]

The Trump administration’s most-favored nations proposal “is not the way to build on a healthcare legacy that should soon include a vaccine to halt the spread of #COVID19.” The policy will force some companies to stop research or scale back operations. https://t.co/tjllIve6D6

[Alliance to Protect Medical Innovation @ProtectMedicine]

In Dr. Matthew Lewin’s quest to develop a universal snakebite antivenom treatment, his team found that the enzyme inhibitor varespladib has positive effects on acute respiratory distress syndrome from #COVID19. https://t.co/4WiNmcO4lO #innovation

[Alliance to Protect Medical Innovation @ProtectMedicine]

.@bmsnews' #psoriasis treatment deucravacitinib met the goals of its Phase 3 study where more patients on BMS's drug scored an "almost clear or clear" skin assessment than patients taking a placebo. https://t.co/UKgrYJyQMi #innovation

[Alliance to Protect Medical Innovation @ProtectMedicine]

57% of doctors who reviewed @biogen's experimental #Alzheimers drug aducanumab believe the drug has a positive effect on Alzheimer's patients. 70% believe the FDA is likely to approve the drug. https://t.co/AGQKsq1pcs #innovation

[Alliance to Protect Medical Innovation @ProtectMedicine]

The Trump administration’s most-favored nation proposal threatens medical #innovation. (Ironic, since innovation is needed more than ever with #COVID19.) This will reduce #biopharma R&D & raise #drugprices for non-Medicare patients. Read our statement: https://t.co/tjllIve6D6

[Alliance to Protect Medical Innovation @ProtectMedicine]

The White House, Congress, and several states' plans to lower #drugprices by importing drugs from Europe and Canada are flawed. They would reduce #biopharma #innovation & Canada is vehemently opposed to exporting its limited drug supply. https://t.co/kOt6sD0OrG

[Alliance to Protect Medical Innovation @ProtectMedicine]

Prescribing "inappropriate" drugs to Americans over the age of 65 increases #drugcosts. A study by @UBuffalo found that older adults spend an extra $128 a year on prescription drugs that should be avoided due to the risks they carry. https://t.co/qG0MQxYK8R

[Alliance to Protect Medical Innovation @ProtectMedicine]

Intellectual property protections are a critical foundation for #biopharma #innovation. They provide fair incentives for innovation, assure innovators have rights, & offer strong enforcement tools for patent holders to defend against infringement. https://t.co/P2AoFVCll2

[Alliance to Protect Medical Innovation @ProtectMedicine]

#Biopharma #innovation has produced a growing reservoir of targeted therapies that offer personalized treatment for patients with cancer or rare diseases. These therapies have improved lung cancer survival rates in men by 35% annually. https://t.co/mdsmpvWeQB